FHI 360 is providing monitoring services for a randomized, placebo-controlled trial to evaluate the safety, immunogenicity and efficacy of a DNA vaccine for the Zika virus that could protect healthy adults and adolescents from acquiring the debilitating virus. The study, funded by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, will enroll more than 2,490 healthy adults and adolescents who live in potential endemic regions in the Caribbean, Central and South America and the United States.
↧
